Published in Curr Opin Neurol Neurosurg on June 01, 1992
Preparation, crystallization and X-ray diffraction analysis to 1.5 A resolution of rat cysteine dioxygenase, a mononuclear iron enzyme responsible for cysteine thiol oxidation. Acta Crystallogr Sect F Struct Biol Cryst Commun (2005) 0.77
Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet (1992) 3.30
Problems in assessing contents of metered dose inhalers. BMJ (1993) 3.07
Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res (1979) 2.61
Starch-Ampicillin Agar for the Quantitative Detection of Aeromonas hydrophila. Appl Environ Microbiol (1985) 1.72
Minimum standards for the management of cleft lip and palate: efforts to close the audit loop. Royal College of Surgeons of England. Ann R Coll Surg Engl (1996) 1.72
CFS hydroxylase cofactor levels in some neurological diseases. J Neurol Neurosurg Psychiatry (1980) 1.59
Raised cerebrospinal-fluid copper concentration in Parkinson's disease. Lancet (1987) 1.48
Plasma cysteine and sulphate levels in patients with motor neurone, Parkinson's and Alzheimer's disease. Neurosci Lett (1990) 1.47
Solubility parameters as predictors of miscibility in solid dispersions. J Pharm Sci (1999) 1.45
Influence of surgeon's experience on speech outcome in cleft lip and palate. Lancet (1999) 1.44
Liposomes and skin: from drug delivery to model membranes. Eur J Pharm Sci (2008) 1.43
Migraine after bone-marrow transplantation. Lancet (1989) 1.43
Updated guidelines for the management of Parkinson's disease. Hosp Med (2001) 1.41
The incidence of impacted teeth. A survey at Harlem hospital. Oral Surg Oral Med Oral Pathol (1970) 1.35
Submandibular duct sialolith of unusual size and shape. J Oral Surg (1975) 1.31
Psychological therapies for the management of chronic and recurrent pain in children and adolescents. Cochrane Database Syst Rev (2003) 1.30
A study of five candidate genes in Parkinson's disease and related neurodegenerative disorders. European Study Group on Atypical Parkinsonism. Neurology (1999) 1.25
Sexual difficulties of chronic pain patients. Clin J Pain (2001) 1.25
Long-term treatment of parkinsonism with bromocriptine. Lancet (1978) 1.24
Cleft lip and palate care in the United Kingdom--the Clinical Standards Advisory Group (CSAG) Study. Part 3: speech outcomes. Cleft Palate Craniofac J (2001) 1.21
Systematic review of outpatient services for chronic pain control. Health Technol Assess (1997) 1.19
Encephalopathy associated with ifosphamide/mesna therapy. Lancet (1985) 1.17
Xenobiotic metabolism in motor neuron disease. Lancet (1988) 1.16
Xenobiotic metabolism in Parkinson's disease. Neurology (1989) 1.16
Oestradiol skin delivery from ultradeformable liposomes: refinement of surfactant concentration. Int J Pharm (2000) 1.15
Cleft lip and palate care in the United Kingdom--the Clinical Standards Advisory Group (CSAG) Study. Part 4: outcome comparisons, training, and conclusions. Cleft Palate Craniofac J (2001) 1.12
Acute angle-closure glaucoma following botulinum toxin injection for blepharospasm. Br J Ophthalmol (1990) 1.10
The development of a battery of measures for assessing physical functioning of chronic pain patients. Pain (1994) 1.08
Spinal cord stimulation and the relief of chronic pain. J Neurol Neurosurg Psychiatry (1987) 1.06
Cleft lip and palate care in the United Kingdom--the Clinical Standards Advisory Group (CSAG) Study. Part 1: background and methodology. Cleft Palate Craniofac J (2001) 1.03
Extrapyramidal reactions to anti-inflammatory drugs. J Neurol Neurosurg Psychiatry (1988) 1.02
Hydroxylase cofactor activity in cerebrospinal fluid of normal subjects and patients with Parkinson's disease. Science (1979) 1.01
Skin delivery of oestradiol from deformable and traditional liposomes: mechanistic studies. J Pharm Pharmacol (1999) 1.01
Experiences with local chemotherapy and immunotherapy in premalignant and malignant skin lesions. Cancer (1970) 1.01
Smoking habits of Florida physicians revisited. JFMA (1972) 1.01
The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2. Gut (2005) 1.00
Stridor during dystonic phases of Parkinson's disease. J Neurol Neurosurg Psychiatry (1987) 1.00
Patients' and professionals' understandings of the causes of chronic pain: blame, responsibility and identity protection. Soc Sci Med (1997) 0.99
Motoneurone disease as manifestation of pesticide toxicity. Lancet (1987) 0.99
Idiopathic dysautonomia treated with intravenous gammaglobulin. Lancet (1996) 0.98
Mechanisms of inhibition of mononuclear cell activation by the iron-chelating agent desferrioxamine. Immunology (1990) 0.98
Derepression of synthesis of the aminoacyl-transfer ribonucleic acid synthetases for the branched-chain amino acids of Escherichia coli. J Bacteriol (1974) 0.98
Skin delivery of 5-fluorouracil from ultradeformable and standard liposomes in-vitro. J Pharm Pharmacol (2001) 0.98
Loss of APC protein expressed by human colonic epithelial cells and the appearance of a specific low-molecular-weight form is associated with apoptosis in vitro. Int J Cancer (1994) 0.97
Bax inhibitor 1 in apoptosis and disease. Oncogene (2011) 0.97
Are the Peer Assessment Rating Index and the Index of Treatment Complexity, Outcome, and Need suitable measures for orthognathic outcomes? Eur J Orthod (2006) 0.96
Characterization of the Aeromonas hydrophila group isolated from retail foods of animal origin. J Clin Microbiol (1989) 0.95
Colorectal carcinogenesis: sequential steps in the in vitro immortalization and transformation of human colonic epithelial cells (review). Anticancer Res (1990) 0.95
The proapoptotic BH3-only protein Bim is downregulated in a subset of colorectal cancers and is repressed by antiapoptotic COX-2/PGE(2) signalling in colorectal adenoma cells. Oncogene (2010) 0.95
Transcriptional upregulation of the insulin-like growth factor binding protein IGFBP-3 by sodium butyrate increases IGF-independent apoptosis in human colonic adenoma-derived epithelial cells. Carcinogenesis (2003) 0.94
S-methylation in motorneuron disease and Parkinson's disease. Lancet (1989) 0.94
Plagiarism, retraction and the future. Hum Reprod (2011) 0.94
Nuclear BAG-1 expression inhibits apoptosis in colorectal adenoma-derived epithelial cells. Apoptosis (2005) 0.94
Terpene penetration enhancers in propylene glycol/water co-solvent systems: effectiveness and mechanism of action. J Pharm Pharmacol (1995) 0.93
Hyponatraemia as a cause of reversible ataxia. Br Med J (Clin Res Ed) (1986) 0.92
Deterioration of Wilson's disease following the start of penicillamine therapy. Arch Neurol (1989) 0.92
Characterization of dihydrates prepared from carbamazepine polymorphs. J Pharm Sci (1996) 0.92
Opiate reduction in chronic pain patients: a comparison of patient-controlled reduction and staff controlled cocktail methods. Pain (1994) 0.92
Toxicity of sulphur-containing compounds to neuronal cell lines. J Neurol Sci (1995) 0.91
Activation of cathepsin B, secreted by a colorectal cancer cell line requires low pH and is mediated by cathepsin D. Int J Cancer (1996) 0.91
Surgery for Parkinson's disease: lack of reliable clinical trial evidence. J Neurol Neurosurg Psychiatry (2003) 0.91
Prospects in NSAID-derived chemoprevention of colorectal cancer. Biochem Soc Trans (2005) 0.90
Guidelines for the management of Parkinson's disease. The Parkinson's Disease Consensus Working Group. Hosp Med (1998) 0.90
Evidence of enhanced lipid peroxidation in the cerebrospinal fluid of patients taking phenothiazines. Lancet (1987) 0.90
Skin hydration and possible shunt route penetration in controlled estradiol delivery from ultradeformable and standard liposomes. J Pharm Pharmacol (2001) 0.90
Cannabinoids and cancer: potential for colorectal cancer therapy. Biochem Soc Trans (2005) 0.89
Bonding of metal attachments to teeth for treatment of mandibular fractures. J Oral Surg (1974) 0.89
An allelic association study of monoamine oxidase B in Parkinson's disease. Ann Neurol (1995) 0.88
IGFBP-3 and apoptosis--a license to kill? Apoptosis (2001) 0.88
Interactions of surfactants (edge activators) and skin penetration enhancers with liposomes. Int J Pharm (2004) 0.88
The retinoblastoma protein (Rb) as an anti-apoptotic factor: expression of Rb is required for the anti-apoptotic function of BAG-1 protein in colorectal tumour cells. Cell Death Dis (2012) 0.87
The neuropathy of the critically ill. Br Med J (Clin Res Ed) (1986) 0.87
Skin delivery of oestradiol from lipid vesicles: importance of liposome structure. Int J Pharm (2000) 0.87
In vitro effect of the cysteine metabolites homocysteic acid, homocysteine and cysteic acid upon human neuronal cell lines. Neurotoxicology (1998) 0.87
The chewing stick: its uses and relationship to oral health. J Prev Dent (1978) 0.86
Self-attempted endodontics--a case report. ASDC J Dent Child (1969) 0.86
Acute epidural abscess. Am J Emerg Med (1987) 0.86
Stochiometrically governed molecular interactions in drug: poloxamer solid dispersions. Int J Pharm (2010) 0.86
Panfacial cellulitis with contralateral orbital cellulitis and blindness after tooth extraction. J Oral Surg (1977) 0.86
Validation of the WHOQOL-100: pain management improves quality of life for chronic pain patients. Clin J Pain (2001) 0.86
Bromocriptine inhibits norepinephrine release. Clin Pharmacol Ther (1979) 0.86
Transcriptional down-regulation of the retinoblastoma protein is associated with differentiation and apoptosis in human colorectal epithelial cells. Br J Cancer (2001) 0.85
Enhancement by terpenes of 5-fluorouracil permeation through the stratum corneum: model solvent approach. J Pharm Pharmacol (1998) 0.85
Mammographic examinations (4030): ten-year clinical experience in a community medical center. Ann Surg (1973) 0.85
Lipid peroxidation and Parkinson's disease. Lancet (1986) 0.85
The process of orthognathic care in an NHS region. Ann R Coll Surg Engl (2009) 0.85
Transdermal delivery from eutectic systems: enhanced permeation of a model drug, ibuprofen. J Control Release (1998) 0.85
Inhibition of radiation-induced G2 delay potentiates cell death by apoptosis and/or the induction of giant cells in colorectal tumor cells with disrupted p53 function. Clin Cancer Res (1997) 0.84
Cytochrome P450 1B1 mRNA in the human central nervous system. Mol Pathol (1998) 0.84
Combined phenyl silane and immunoaffinity column cleanup with liquid chromatography for determination of ochratoxin A in roasted coffee: collaborative study. J AOAC Int (2001) 0.84
BAG-1 interacts with the p50-p50 homodimeric NF-κB complex: implications for colorectal carcinogenesis. Oncogene (2011) 0.84
Mechanistic study into the enhanced transdermal permeation of a model beta-blocker, propranolol, by fatty acids: a melting point depression effect. Int J Pharm (2001) 0.84
Chromosomal localisation of genes coding for human and mouse liver cytosolic cysteine dioxygenase. Ann Hum Genet (1996) 0.84
Nomalike lesion in a patient with chronic lymphocytic leukemia. Review of the literature and report of a case. Oral Surg Oral Med Oral Pathol (1976) 0.84
Renal localisation of rat cysteine dioxygenase. Nephron (2001) 0.83
Human cysteine dioxygenase type I: primary structure derived from base sequencing of cDNA. Biochim Biophys Acta (1994) 0.83
Familial paroxysmal dystonia induced by exercise. J Neurol Neurosurg Psychiatry (1984) 0.83
Plasma membrane phospholipid integrity and orientation during hypoxic and toxic proximal tubular attack. Kidney Int (1999) 0.83
Intracellular or intercellular localization of the polar pathway of penetration across stratum corneum. J Pharm Sci (1998) 0.83